The biochemical bases of the placebo effect.
A great variety of medical conditions are subject to the placebo effect. Although there is mounting evidence to suggest that the placebo effect is related to the expectation of clinical benefit, little is still known about the biochemical bases underlying placebo responses. Positron emission tomography studies have recently shown that the placebo effect in Parkinson's disease, pain, and depression is related to the activation of the limbic circuitry. The observation that placebo administration induces the release of dopamine in the ventral striatum of patients with Parkinson's disease suggests a link between the placebo effect and reward mechanisms. In addition to Parkinson's disease, the placebo-reward model may also apply to other disorders. However, the relative contribution of the different neurotransmitters and neuropeptides that are known to be involved in modulating the activity of the limbic system may be disease-specific. Thus, while the placebo-induced clinical benefit observed in Parkinson's disease would mostly reflect the release of dopamine in the dorsal striatum, the activation of opioid and serotonin pathways could be particularly implicated in mediating placebo responses encountered in pain and depression, respectively.
Division of Neurology, Hospital A. Marcide, 15405 Ferrol, A Coruña, Spain. rfuente@medynet.com
Raúl
R
de la Fuente-Fernández
A Jon
AJ
Stoessl
D001669:Biochemical Phenomena; D001671:Biochemistry; D002986:Clinical Trials as Topic / Q000379:methods; D003863:Depression / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004341:Drug Evaluation / Q000379:methods; D006801:Humans; D008032:Limbic System / Q000378:metabolism*; D009294:Narcotics / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism; D015990:Placebo Effect; D012201:Reward; D012701:Serotonin / Q000378:metabolism
D009294:Narcotics; D012701:Serotonin; D004298:Dopamine